Henry S Heine

Henry S Heine,

PRG DIR & ASO PROF

Department: MD-INST FOR THERAPEUTIC INNOV
Business Phone: (407) 313-7062

Teaching Profile

Courses Taught
2018-2021
GMS5905 Special Topics in Biomedical Sciences
2018
GMS7979 Advanced Research

Publications

2021
In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.
Antimicrobial agents and chemotherapy. 65(5) [DOI] 10.1128/AAC.02385-20. [PMID] 33593844.
2020
Validated Methods for Removing Select Agent Samples from Biosafety Level 3 Laboratories.
Emerging infectious diseases. 26(11):2586-2590 [DOI] 10.3201/eid2611.191630. [PMID] 33079040.
2019
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.
Antimicrobial agents and chemotherapy. 63(12) [DOI] 10.1128/AAC.00834-19. [PMID] 31548183.
2017
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
Antimicrobial agents and chemotherapy. 61(9) [DOI] 10.1128/AAC.00788-17. [PMID] 28696235.
2017
In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.
Antimicrobial agents and chemotherapy. 61(9) [DOI] 10.1128/AAC.00612-17. [PMID] 28674048.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Bacillus Anthracis Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial Agents and Chemotherapy. 61(10) [DOI] 10.1128/AAC.01103-17.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Francisella Tularensis Schu S4 Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial agents and chemotherapy. 61(8) [DOI] 10.1128/AAC.00448-17. [PMID] 28559261.
2016
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrobial agents and chemotherapy. 60(3):1834-40 [DOI] 10.1128/AAC.02887-15. [PMID] 26824958.
2015
In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.
Antimicrobial agents and chemotherapy. 59(4):1919-21 [DOI] 10.1128/AAC.04548-14. [PMID] 25583720.
2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Antimicrobial agents and chemotherapy. 58(6):3276-84 [DOI] 10.1128/AAC.02420-14. [PMID] 24687492.
2013
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
Antimicrobial agents and chemotherapy. 57(5):2010-5 [DOI] 10.1128/AAC.02504-12. [PMID] 23403418.
2012
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy. 56(1):513-7 [DOI] 10.1128/AAC.05724-11. [PMID] 22064542.
2012
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy. 56(3):1229-39 [DOI] 10.1128/AAC.01109-10. [PMID] 22155821.
2011
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy. 55(6):2623-8 [DOI] 10.1128/AAC.01374-10. [PMID] 21486959.
2011
Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.
Journal of clinical microbiology. 49(5):1956-60 [DOI] 10.1128/JCM.00142-11. [PMID] 21411569.
2011
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy. 55(2):822-30 [DOI] 10.1128/AAC.00818-10. [PMID] 21115791.
2010
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
Antimicrobial agents and chemotherapy. 54(3):991-6 [DOI] 10.1128/AAC.00820-09. [PMID] 20047912.
2010
Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Antimicrobial agents and chemotherapy. 54(10):4471-3 [DOI] 10.1128/AAC.00210-10. [PMID] 20643899.
2010
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Molecular and cellular probes. 24(3):154-60 [DOI] 10.1016/j.mcp.2010.01.003. [PMID] 20100564.
2010
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Antimicrobial agents and chemotherapy. 54(5):1678-83 [DOI] 10.1128/AAC.00737-08. [PMID] 20145081.
2009
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy. 53(11):4718-25 [DOI] 10.1128/AAC.00802-09. [PMID] 19687233.
2008
Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies.
Carbohydrate research. 343(16):2783-8 [DOI] 10.1016/j.carres.2008.05.021. [PMID] 18558401.
2008
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
Antimicrobial agents and chemotherapy. 52(9):3350-7 [DOI] 10.1128/AAC.00360-08. [PMID] 18606841.
2008
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy. 52(11):3973-9 [DOI] 10.1128/AAC.00453-08. [PMID] 18725437.
2008
Petrobactin is produced by both pathogenic and non-pathogenic isolates of the Bacillus cereus group of bacteria.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 21(5):581-9 [DOI] 10.1007/s10534-008-9144-9. [PMID] 18459058.
2008
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy. 52(7):2486-96 [DOI] 10.1128/AAC.01439-07. [PMID] 18458134.
2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases. 196(5):782-7 [PMID] 17674322.
2007
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Antimicrobial agents and chemotherapy. 51(4):1373-9 [PMID] 17296745.
2007
Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.
Journal of medicinal chemistry. 50(15):3681-5 [PMID] 17608397.
2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Antimicrobial agents and chemotherapy. 51(12):4351-5 [PMID] 17875992.
2006
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
Proceedings of the National Academy of Sciences of the United States of America. 103(20):7813-6 [PMID] 16672361.
2005
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy. 49(12):5099-106 [PMID] 16304178.
2001
In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test.
Antimicrobial agents and chemotherapy. 45(7):2119-21 [PMID] 11408233.

Grants

Sep 2022 ACTIVE
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST via DEFENSE THREAT REDUCTION AGENCY
Apr 2022 ACTIVE
In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels
Role: Co-Investigator
Funding: CENTER FOR DISCOVERY AND INNOVATION via NATL INST OF HLTH NIAID
Feb 2022 – Jun 2022
Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Feb 2022 – Mar 2022
In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels
Role: Principal Investigator
Funding: PROKARYOTICS
Jan 2022 ACTIVE
Merck Study Agreement
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Aug 2021 – Aug 2022
In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Mar 2021 ACTIVE
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Role: Principal Investigator
Funding: ADVANCED TECHNOLOGY INTERNATIONAL via DEFENSE THREAT REDUCTION AGENCY
Feb 2021 – Jun 2021
Evaluation of air purification methods for SARS-CoV-2
Role: Co-Investigator
Funding: HELEN OF TROY
Feb 2021 – May 2021
Teixobactin Development for Anthrax
Role: Principal Investigator
Funding: NOVOBIOTIC PHARMACEUTICALS via NATL INST OF HLTH NIAID
Nov 2020 – Dec 2021
Project Bioshield
Role: Co-Investigator
Funding: SPERO THERAPEUTICS
Oct 2020 – Nov 2020
MICs for Wockhardt WCK-5222
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
May 2020 – Jul 2020
KBP Biosciences Research Agreement – In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: KBP BIOSCIENCES USA
Apr 2020 ACTIVE
Battelle Subcontract 778380 SAB Year 1
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST via DEFENSE THREAT REDUCTION AGENCY
Feb 2020 – Sep 2022
Evaluation of antimicrobial peptides for Biodefense
Role: Principal Investigator
Funding: UNIV OF TEXAS AUSTIN via DEFENSE THREAT REDUCTION AGENCY
Apr 2019 – Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Apr 2019 – Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 PK Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Jan 2019 – Oct 2020
In vitro testing of the 40 isolate panel of B. pseudomallei isolates
Role: Principal Investigator
Funding: VENATORX PHARMACEUTICALS via DEFENSE THREAT REDUCTION AGENCY
Nov 2018 – Apr 2019
In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens
Role: Principal Investigator
Funding: SPERO THERAPEUTICS via NATL INST OF HLTH NIAID
Jul 2018 – Mar 2019
Confirmatory Efficacy Study in Bp Infected Mice
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Feb 2018 – Oct 2018
Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Nov 2017 – Jun 2018
Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Nov 2017 – Jan 2018
Evaluation of EBX-205 against of B. Pseudomallei in virto
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Oct 2017 – Feb 2018
MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei.
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
Sep 2017 – Dec 2017
Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Sep 2017 – Sep 2018
Pharmacokinetic analysis of nonhuman primate data for US Army
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Aug 2017 – Jan 2018
ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Aug 2017 – Jan 2018
Exhibit N – MIC testing of BSC 3 extended MIC Panel in connection with Achaogens C-Scape project as outlined in University of Florida proposal ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Aug 2017 – Jan 2018
ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
May 2017 – Aug 2017
Salary for protocol development and ACURO review
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Mar 2017 – May 2017
WITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Oct 2014 – Dec 2017
HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents
Role: Project Manager
Funding: EMERGENT BIOSOLUTIONS via US DEPT OF DEFENSE
Sep 2014 – Dec 2016
Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Jul 2012 – Jul 2017
In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs.
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2012 – Apr 2016
EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1
Role: Principal Investigator
Funding: GLAXO SMITHKLINE via US DEPT OF DEFENSE

Contact Details

Phones:
Business:
(407) 313-7062
Emails:
Addresses:
Business Mailing:
RESEARCH ACADEMIC CENTER AT LAKE NONA
6550 SANGER RD
ITI
ORLANDO FL 328277445
Business Street:
U. FLORIDA RESEARCH ACADEMIC CENTER AT LAKE
ITI, DEPT MEDICINE
ORLANDO FL 32832